1
|
Ghafuri DL, Abdullahi SU, Dambatta AH, Galadanci J, Tabari MA, Bello-Manga H, Idris N, Inuwa H, Tijjani A, Suleiman AA, Jibir BW, Gambo S, Gambo AI, Khalifa Y, Haliru L, Abdulrasheed S, Zakari MA, Greene BC, Trevathan E, Jordan LC, Aliyu MH, Baumann AA, DeBaun MR. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework. J Pediatr Hematol Oncol 2022; 44:e56-e61. [PMID: 34001783 PMCID: PMC8728755 DOI: 10.1097/mph.0000000000002179] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Accepted: 03/04/2021] [Indexed: 11/25/2022]
Abstract
We used the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework to evaluate a Stroke Prevention Team's readiness to prevent strokes in children with sickle cell anemia living in northern Nigeria. The NIH sponsored Stroke Prevention Trial in Nigeria included a goal of a sustainable stroke prevention program. The program's 1-year reach for transcranial Doppler screening was 14.7% (4710/32,000) of which 6.0% (281/4710) had abnormal velocities (≥200 cm/s). All participants with abnormal transcranial Doppler velocities were started on hydroxyurea (effectiveness). The leaders of all 5 hospitals agreed to adopt the program. After 1 year, program-implementation and maintenance rates were 100%, demonstrating the program's feasibility and short-term sustainability.
Collapse
Affiliation(s)
- Djamila L. Ghafuri
- Department of Pediatrics, Vanderbilt University Medical Center, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease
| | | | | | | | | | | | | | | | | | | | | | - Safiya Gambo
- Pediatrics, Murtala Mohammed Specialist Hospital
| | | | - Yusuf Khalifa
- Department of Administration, Aminu Kano Teaching Hospital, Kano
| | - Lawal Haliru
- Department of Pediatrics, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria
| | - Sani Abdulrasheed
- Department of Pediatrics, Barau Dikko Teaching Hospital/Kaduna State University, Kaduna, Nigeria
| | | | - Brittany C. Greene
- Department of Pediatrics, Vanderbilt University Medical Center, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease
| | - Edwin Trevathan
- Department of Neurology, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN
| | - Lori C. Jordan
- Department of Pediatrics, Division of Pediatric Neurology
| | - Muktar H. Aliyu
- Health Policy, Vanderbilt Institute for Global Health, Vanderbilt University Medical Center
| | - Ana A. Baumann
- Brown School of Social Work, Washington University of St. Louis, St. Louis, MO
| | - Michael R. DeBaun
- Department of Pediatrics, Vanderbilt University Medical Center, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease
| |
Collapse
|
2
|
Tabari MA, Poźniak B, Youssefi MR, Roudaki Sarvandani MR, Giorgi M. Comparative pharmacokinetics of metronidazole in healthy and Trichomonas gallinae infected pigeons ( Columba livia, var. domestica). Br Poult Sci 2021; 62:485-491. [PMID: 33491469 DOI: 10.1080/00071668.2021.1881043] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
1. This study investigated the pharmacokinetics of metronidazole after intravenous (i.v.) and oral administration to healthy and experimentally Trichomonas gallinae-infected pigeons, and determined the in vitro antiprotozoal activity of metronidazole against T. gallinae.2. Twelve pigeons which were experimentally infected to T. gallinae and twelve healthy pigeons received metronidazole at the dose of 25 mg/kg by oral or i.v. administration. Serial blood sampling was used for pharmacokinetic analysis. The metronidazole minimum lethal concentration (MLC) and the concentration killing 50% of the trophozoites (LC50) in the culture media were determined.3. In vitro data showed that the 24 h LC50 and MLC of metronidazole were 0.31 and 25 µg/ml, respectively. In vivo results showed no statistical differences between pharmacokinetics in infected and non-infected pigeons for both routes of administration. The area under the curve was statistically higher after the i.v. administration in both infected and healthy pigeons. The mean oral bioavailability was similar in the infected (83.8%) and the healthy (81.5%) birds.4. In conclusion, the pharmacokinetics of metronidazole in pigeons was not affected by experimentally-induced trichomoniasis. Despite in vitro susceptibility testing, which showed probable resistance of the isolated T. gallinae to metronidazole, five-day oral treatment of infected pigeons with 25 mg/kg metronidazole twice a day resulted in total eradication of trophozoites recovered in crop lavage of infected birds.
Collapse
Affiliation(s)
- M A Tabari
- Faculty of Veterinary Medicine, Amol University of Special Modern Technologies, Amol, Iran
| | - B Poźniak
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wrocław, Poland
| | - M R Youssefi
- Department of Veterinary Parasitology, Babol Branch, Islamic Azad University, Babol, Iran
| | | | - M Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy.,Veterinary Medicine PhD School, University of Sassari, Sassari, Italy
| |
Collapse
|
3
|
Abdullahi SU, Wudil BJ, Bello-Manga H, Musa AB, Gambo S, Galadanci NA, Aminu H, Gaya AT, Sanusi S, Tabari MA, Galadanci A, Borodo A, Abba MS, Dambatta AH, Haliru L, Gambo A, Cassell H, Rodeghier M, Ghafuri DL, Greene BVC, Neville K, Kassim AA, Kirkham F, Trevathan E, Jordan LC, Aliyu MH, DeBaun MR. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial. Pediatr Hematol Oncol 2021; 38:49-64. [PMID: 33236662 PMCID: PMC7954909 DOI: 10.1080/08880018.2020.1810183] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Strokes in children with sickle cell anemia (SCA) are associated with significant morbidity and premature death. Primary stroke prevention in children with SCA involves screening for abnormal transcranial Doppler (TCD) velocity coupled with regular blood transfusion therapy for children with abnormal velocities, for at least one year. However, in Africa, where the majority of children with SCA live, regular blood transfusions are not feasible due to inadequate supply of safe blood, cost, and the reluctance of caregivers to accept transfusion therapy for their children. We describe the Primary Prevention of Stroke in Children with Sickle Cell Disease in Nigeria Trial [StrokePreventioninNigeria (SPRING) trial, NCT02560935], a three-center double-blinded randomized controlled Phase III clinical trial to 1) determine the efficacy of moderate fixed-dose (20 mg/kg/day) versus low fixed-dose (10 mg/kg/day) hydroxyurea therapy for primary stroke prevention; 2) determine the efficacy of moderate fixed-dose hydroxyurea for decreasing the incidence of all cause-hospitalization (pain, acute chest syndrome, infection, other) compared to low fixed-dose hydroxyurea. We will test the primary hypothesis that there will be a 66% relative risk reduction of strokes in children with SCA and abnormal TCD measurements, randomly allocated, for a minimum of three years to receive moderate fixed-dose versus low fixed-dose hydroxyurea (total n = 220). The results of this trial will advance the care of children with SCA in sub-Saharan Africa, while improving research capacity for future studies to prevent strokes in children with SCA.
Collapse
Affiliation(s)
- Shehu U. Abdullahi
- Department of Pediatrics, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Binta J. Wudil
- Department of Pediatrics, Hasiya Bayero Specialist Hospital, Kano Nigeria
| | - Halima Bello-Manga
- Department of Hematology and Blood Transfusion, Barau-Dikko Teaching Hospital, Kaduna Nigeria
| | - Aisha B. Musa
- Department of Pediatrics, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Safiya Gambo
- Department of Pediatrics, Murtala Mohammed Specialist Hospital, Kano, Nigeria
| | - Najibah A. Galadanci
- Department of Epidemiology, School of Public health, University of Alabama at Birmingham, Alabama, USA
| | - Hauwa Aminu
- Department of Pediatrics, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Aliyu Tijjani Gaya
- Department of Pediatrics, Murtala Mohammed Specialist Hospital, Kano, Nigeria
| | - Surayya Sanusi
- Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Musa A. Tabari
- Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Aisha Galadanci
- Department of Hematology and Blood Transfusion, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Awwal Borodo
- Department of Medicine, Murtala Mohammed Specialist Hospital
| | - Muhammed S. Abba
- Department of Pharmacy, Bayero University, Aminu Kano Teaching Hospital
| | - Abdu H. Dambatta
- Department of Community Medicine, Bayero University, Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Lawal Haliru
- Department of Pediatrics, Kaduna State University, Barau Dikko Teaching Hospital
| | - Awwal Gambo
- Department of Pediatrics, Murtala Mohammed Specialist Hospital, Kano, Nigeria
| | - Holly Cassell
- Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - Djamila L. Ghafuri
- Department of Pediatrics, Division of Hematology and Oncology, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Brittany V. Covert Greene
- Department of Pediatrics, Division of Hematology and Oncology, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Kathleen Neville
- Department of Pediatrics, University of Kansas for Medical Sciences, Little Rock, AR, USA
| | - Adetola A. Kassim
- Department of Pediatrics, Division of Hematology and Oncology, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA;,Department of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Fenella Kirkham
- Department of Pediatrics, UCL Great Ormond Street Institute of Child Health, London, UK
| | - Edwin Trevathan
- Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Lori C. Jordan
- Department of Pediatrics, Division of Pediatric Neurology, Vanderbilt University Medical Center, Nashville, TN USA
| | - Muktar H. Aliyu
- Vanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Michael R. DeBaun
- Department of Pediatrics, Division of Hematology and Oncology, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA;,Correspondence: Michael R. DeBaun, MD, MPH, Department of Pediatrics, Division of Hematology/ Oncology, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, 2525 West End Avenue, Suite 750, Nashville, TN 37203-1738, USA, Phone: (615) 875-3040 Fax: (615) 875-3055,
| |
Collapse
|
4
|
Galadanci NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, Aminu H, Tijjani A, Abba MS, Tabari MA, Galadanci A, Borodo AM, Belonwu R, Salihu AS, Rodeghier M, Ghafuri DL, Covert C Greene BV, Neville K, Kassim AA, Kirkham FJ, Jordan LC, Aliyu MH, DeBaun MR. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial. Am J Hematol 2020; 95:E247-E250. [PMID: 32510680 DOI: 10.1002/ajh.25900] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Accepted: 05/31/2020] [Indexed: 01/04/2023]
Affiliation(s)
- Najibah A. Galadanci
- Department of Epidemiology, School of Public Health University of Alabama at Birmingham Birmingham Alabama
| | - Shehu U. Abdullahi
- Department of Pediatrics Bayero University/Aminu Kano Teaching Hospital Kano Nigeria
| | - Shehi Ali Abubakar
- Department of Radiology Bayero University/Aminu Kano Teaching Hospital Kano Nigeria
| | - Binta Wudil Jibir
- Department of Pediatrics Hasiya Bayero Childrenʼs Hospital Kano Nigeria
| | - Hauwa Aminu
- Murtala Mohammed Specialist Hospital Kano Nigeria
| | | | - Muhammad S. Abba
- Department of Pharmacy Aminu Kano Teaching Hospital Kano Nigeria
| | - Musa A. Tabari
- Department of Radiology Barau‐Dikko Teaching Hospital Kaduna Nigeria
| | - Aisha Galadanci
- Department of Hematology Bayero University/Aminu Kano Teaching Hospital Kano Nigeria
| | - Awwal Musa Borodo
- Department of Medicine Murtala Muhammad Specialist Hospital Kano Nigeria
| | - Raymond Belonwu
- Department of Pediatrics Bayero University/Aminu Kano Teaching Hospital Kano Nigeria
| | - Auwal S. Salihu
- Department of Psychiatry Bayero University/Aminu Kano Teaching Hospital Kano Nigeria
| | | | - Djamila L. Ghafuri
- Division of Hematology and Oncology, Department of Pediatrics Vanderbilt‐Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center Nashville Tennessee
| | - Brittany V. Covert C Greene
- Division of Hematology and Oncology, Department of Pediatrics Vanderbilt‐Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center Nashville Tennessee
| | - Kathleen Neville
- Department of Pediatrics, Divisions of Pediatric Hematology‐Oncology and Clinical Pharmacology and Toxicology University of Arkansas for Medical Sciences Little Rock Arkansas
| | - Adetola A. Kassim
- Division of Hematology and Oncology Department of Medicine Vanderbilt University School of Medicine Nashville Tennessee
| | - Fenella J. Kirkham
- Department of Pediatrics University College of London, Great Ormond Street Institute of Child Health London UK
| | - Lori C. Jordan
- Division of Pediatric Neurology, Department of Pediatrics Vanderbilt University Medical Center Nashville Tennessee
| | | | - Michael R. DeBaun
- Division of Hematology and Oncology, Department of Pediatrics Vanderbilt‐Meharry of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center Nashville Tennessee
| |
Collapse
|
5
|
Tabari MA, Fathi SAA, Nouri-Ganbalani G, Moumeni A, Razmjou J. Antixenosis and Antibiosis Resistance in Rice Cultivars against Chilo suppressalis (Walker) (Lepidoptera: Crambidae). Neotrop Entomol 2017; 46:452-460. [PMID: 28039677 DOI: 10.1007/s13744-016-0479-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Accepted: 12/12/2016] [Indexed: 06/06/2023]
Abstract
The striped stem borer, Chilo suppressalis (Walker) (Lepidoptera: Crambidae), is an important pest afflicting rice in most rice-growing countries in the world. Deliniating the categories of resistance in rice genotypes under field conditions could be helpful in managment of this pest. Two categories of resistance, antixenosis and antibiosis, were examined in ten popular and diverse rice genotypes of different origin that had been selected for their resistance to the striped stem borer in a previous study. Significant differences were found between genotypes for the number of egg masses, number of eggs, preference index, larval and pupal weight, larval development time, larval survival rate, larval mine length, and leaf trichome density. It was found that the rice genotypes Novator, A7801, and Nemat had the more pronounced antixenosis-type resistance, whereas AB1 and Shirodi had better antiobiosis-type resistance. Interestingly, the rice genotype AN-74 for which Nemat is the parental line showed both types of resistance and could be effectively used in an integrated pest management of the rice striped stem borer.
Collapse
Affiliation(s)
- M A Tabari
- Dept of Plant Protection, Faculty of Agricultural Science, Univ of Mohaghegh Ardabili, Ardabil, Iran
- Rice Research Institute of Iran, Mazandaran Branch, Agricultural Research, Education and Extension Organization (AREEO), Amol, Iran
| | - S A A Fathi
- Dept of Plant Protection, Faculty of Agricultural Science, Univ of Mohaghegh Ardabili, Ardabil, Iran
| | - G Nouri-Ganbalani
- Dept of Plant Protection, Faculty of Agricultural Science, Univ of Mohaghegh Ardabili, Ardabil, Iran
| | - A Moumeni
- Rice Research Institute of Iran, Mazandaran Branch, Agricultural Research, Education and Extension Organization (AREEO), Amol, Iran.
| | - J Razmjou
- Dept of Plant Protection, Faculty of Agricultural Science, Univ of Mohaghegh Ardabili, Ardabil, Iran
| |
Collapse
|
6
|
Galadanci NA, Abdullahi SU, Tabari MA, Abubakar S, Belonwu R, Salihu A, Neville K, Kirkham F, Inusa B, Shyr Y, Phillips S, Kassim AA, Jordan LC, Aliyu MH, Covert BV, DeBaun MR. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial. Pediatr Blood Cancer 2015; 62:395-401. [PMID: 25399822 PMCID: PMC4304992 DOI: 10.1002/pbc.25289] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Accepted: 09/05/2014] [Indexed: 11/06/2022]
Abstract
BACKGROUND The majority of children with sickle cell disease (SCD), approximately 75%, are born in sub-Saharan Africa. For children with elevated transcranial Doppler (TCD) velocity, regular blood transfusion therapy for primary stroke prevention is standard care in high income countries, but is not feasible in sub-Saharan Africa. PROCEDURE In the first U.S. National Institute of Health (NIH) sponsored SCD clinical trial in sub-Saharan Africa, we describe the protocol and challenges unique to starting a clinical trial in this region. We are conducting a single arm pilot trial of hydroxyurea therapy in children with TCD velocity ≥200 cm/sec in the middle cerebral arteries. Eligible children will be placed on hydroxyurea (n = 40) and followed for 3 years at Aminu Kano Teaching Hospital, Nigeria. Adherence will be measured via the Morisky Scale and adverse events will be determined based on hospitalization. RESULTS Originally, a randomized placebo trial was planned; however, placebo was not approved by the local Ethics Committee. Hence a single arm trial of hydroxyurea will be conducted and five controls per patient with normal TCD measurements will be followed to compare the rate of adverse events to those with abnormal TCD measurements taking hydroxyurea. Using non-NIH funding, over 9 months, multiple face-to-face investigator meetings were conducted to facilitate training. CONCLUSION A hydroxyurea trial (NCT01801423) for children with SCD is feasible in sub-Saharan Africa; however, extensive training and resources are needed to build a global patient oriented multi-disciplinary research team with a common purpose.
Collapse
Affiliation(s)
- Najibah A. Galadanci
- Department of Haematology and Blood Transfusion, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Shehu U. Abdullahi
- Department of Pediatrics, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Musa A. Tabari
- Department of Radiology, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Shehi Abubakar
- Department of Radiology, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Raymond Belonwu
- Department of Pediatrics, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Auwal Salihu
- Department of Psychiatry, Bayero University/Aminu Kano Teaching Hospital, Kano, Nigeria
| | - Kathleen Neville
- Department of Pediatric Hematology/Oncology, University of Missouri-Kansas City School of Medicine, USA
| | - Fenella Kirkham
- Department of Pediatrics, University College of London Institute of Child Health, London, UK
| | - Baba Inusa
- Department of Pediatrics, Evelina's Children's Hospital, Guy's and St. Thomas’, London, UK
| | - Yu Shyr
- Department of Biostatistics, Vanderbilt University School of Medicine,Nashville, TN, USA
| | - Sharon Phillips
- Department of Biostatistics, Vanderbilt University School of Medicine,Nashville, TN, USA
| | - Adetola A. Kassim
- Department of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Lori C. Jordan
- Department of Pediatrics, Neurology, Vanderbilt University Medical Center, Nashville, TN USA
| | | | - Brittany V. Covert
- Department of Pediatrics, Hematology and Oncology, Vanderbilt-Meharry-Matthew Walker Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Michael R. DeBaun
- Department of Pediatrics, Hematology and Oncology, Vanderbilt-Meharry-Matthew Walker Center of Excellence in Sickle Cell Disease, Vanderbilt University Medical Center, Nashville, TN, USA,Correspondence and reprint requests to: Michael R. DeBaun, MD, MPH, Vanderbilt-Meharry-Matthew Walker Center of Excellence in Sickle Cell Disease, Department of Pediatrics, Vanderbilt University School of Medicine, 2200 Children's Way, Room 11206 DOT, Nashville, TN 37232-9000, USA, Phone: 615-875-3040, Fax: 615-875-3055,
| |
Collapse
|